Kyntra Bio, Inc. (KYNB)
KYNBNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$3.86
-0.0400 (-1.03%) today
Regular session, Nov 10, 3:12 PM ET
- Market cap
- $15.63m
- P/E
- –
- EPS, last 4 quarters
- $-13.64
- Dividend yield
- –
- Day range
- $3.52 to $4.10
- 52-week range
- $3.60 to $11.19
- Average volume
- 24.0k
- Previous close
- $3.90
Analysts
5 coveringBuy4 buy, 1 hold, 0 sell
Targets a year out average $38.50, +897.4% from here
Earnings
next estimate $-3.66Next report
Sep 2025
+59.9%
Dec 2025
+7.2%
Mar 2026
-11.3%
Jun 2026
-47.2%
estimate reported, and the surprise
Financials
| Quarter | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | $1.35m | $1.07m | $1.28m | $3.74m |
| Gross profit | $1.26m | $1.13m | $999.0k | -$368.0k |
| Operating income | -$12.05m | -$5.41m | -$13.51m | -$13.82m |
| Net income | -$7.60m | $200.64m | -$14.22m | -$15.20m |
Last four quarters: revenue $7.44m, margin 2199.4%, free cash flow –
News
8 latest- Lake Street Initiates Coverage of Kyntra Bio with BuyFintel · Sep 17, 2026
- Kyntra Bio (KYNB) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 20, 2026
- Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue EstimatesZacks · Aug 13, 2026
- Kamada (KMDA) Q2 Earnings and Revenues Surpass EstimatesZacks · Aug 12, 2026
- Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?Zacks · Aug 3, 2026
- Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue EstimatesZacks · Jul 30, 2026
- NovoCure (NVCR) Reports Q2 Loss, Beats Revenue EstimatesZacks · Jul 23, 2026
- Kyntra Reports Phase 3 MATTERHORN Data For Roxadustat In LR-MDS; U.S. Phase 3 Planned In H2 2026 RTTNews · Jun 12, 2026
The company
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (, EVRENZO) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- kyntrabio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.